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We evaluated the prognostic signiﬁcance of lymph node ratio (LNR), number of metastatic lymph nodes divided by number of
removed nodes in 924 breast carcinoma patients with 1–3 metastatic axillary lymph node(s). The most signiﬁcant LNR threshold
value separating patients in low- and high-risk groups with signiﬁcant survival diﬀerence was 0.20 for disease-free survival (P<
0.001), 0.30 for locoregional recurrence-free survival (P<0.001), and 0.15 for distant metastasis-free survival (P<0.001), and
the patients with lower LNR had better survival. All three LNR threshold values had independent prognostic signiﬁcance in Cox
analysis (P<0.001 for all three of them). In conclusion, LNR is a useful tool in separating breast carcinoma patients with 1–3
metastatic lymph node(s) into low- and high-risk prognostic groups.
1.Introduction
Axillary lymph node status is the most important prog-
nostic factor in breast carcinoma and prognosis worsens
with increasing number of metastatic lymph nodes [1, 2].
According to the American Joint Committee on Cancer
(AJCC)/International Union Against Cancer (UICC) tumor
(T)-node (N)-metastasis (M) classiﬁcation, nodal disease
is classiﬁed in three groups based on the number of
axillary metastatic lymph nodes: N1, 1–3 metastatic lymph
node(s), N2, 4–9 metastatic lymph nodes and N3, 10 or
more metastatic lymph nodes [3]. However, the number of
metastatic lymph nodes depends on the number of removed
lymph nodes that are dissected by the surgeon and examined
by the pathologist. Various studies have shown that the
number of metastatic lymph nodes is greater with increasing
number of removed lymph nodes [4–12]. It is diﬃcult
to assess the axillary lymph node status reliably without
removing suﬃcient numbers of lymph nodes depending on
the surgeon and/or pathologist.
Studies conducted in recent years indicate that the ratio
of the number of metastatic lymph nodes to the number of
removed lymph nodes denoted as lymph node ratio (LNR)
provide a more useful prognostic information compared
to nodal disease classiﬁcation according to the number
of metastatic lymph nodes [9, 13–16]. A review on the
prognostic value of LNR indicated that the threshold value
of clinically signiﬁcant LNR varies in diﬀerent studies and
emphasized that these studies vary by sampling size and
tumor stage [17]. Until now, analysis was made mostly
in all lymph node-positive patients, without subdivision
in N1, N2, and N3 disease groups in the LNR studies
[9, 13, 14, 16, 18–23]. LNR threshold value separating the
whole series in two prognostic groups with signiﬁcantly
diﬀerent survival was given as 0.20 [18, 24] and 0.25 [9].
In three series including patients with N2 and N3 disease
receiving adjuvant high-dose chemotherapy with stem-cell
support, LNR threshold value of prognostic signiﬁcance was
determined as 0.80 by Nieto et al. [25] and Schneeweiss
et al. [26], and 0.70 by Bolwell et al. [27]. Our group2 ISRN Oncology
determined the LNR threshold value as 0.80 in a previous
study including patients with T1,2,3N3M0 disease [28]. In
all of the above-mentioned studies patients with higher LNR
had signiﬁcantly worse prognosis compared to those with
lower LNR. A striking result from these studies was that the
LNRthresholdvalueofprognosticsigniﬁcancewasgreaterin
series excluding N1 disease, compared to those including it.
Based on this, we proposed that identifying a separate LNR
threshold value for each N disease group may be useful [28].
Fortin et al. recommended axillary radiotherapy for patients
with a LNR 0.40 or above in the group with 1–3 metastatic
lymph node(s) and for patients with a LNR 0.50 or above
in the group with 4 or more metastatic lymph nodes among
T1-T2 node-positive patients [7]. There is limited number of
studies investigating the prognostic value of LNR in patients
with only N1 disease [29–31].
In this study, we evaluated the prognostic signiﬁcance
of the number of removed and metastatic lymph nodes
and LNR in breast carcinoma patients with 1–3 axillary
metastatic lymph node(s).
2.MaterialsandMethods
2.1. Patients. We retrospectively reviewed the ﬁle records
of women who underwent surgery for breast carcinoma
between January 1993 and December 2001 and who were
t h e nf o l l o w e du pi nS BO k m e y d a n ı Training and Research
Hospital. Inclusion criteria for the patients were a histologi-
cal diagnosis of unilateral invasive breast carcinoma, no pre-
viousorconcomitantmalignantdisease,known pathological
tumor size (patients with T4 tumor were not included),
axillary 1–3 lymph node(s) metastasis, no metastasis in ipsi-
lateral internal mammary or supraclavicular lymph nodes
and distant site at the time of diagnosis, microscopically
tumor-free surgical margins, completion of adjuvant therapy
planned according to standard therapy protocols, and a
follow-up period of at least ﬁve years. A total of 924 patients
(including 174 patients who underwent surgery at the study
hospital) who met these criteria were enrolled in the current
study. Clinicopathological and treatment features of the
patients are shown in Table 1.
Follow-up data were obtained from ﬁle records and, in
some patients, through telephone calls. The endpoint of the
study was disease recurrence. Locoregional recurrence was
deﬁned as the ﬁrst site of recurrence involving the chest
wall (local) or/and ipsilateral axillary, supraclavicular, and
internal mammary lymph nodes (regional). Locoregional
recurrence concurrent with distant metastasis was recorded
as locoregional recurrence. First disease recurrence was
recorded as distant metastasis if it was either distant metasta-
sis or concurrent distant metastasis and locoregional recur-
rence. Disease-free survival (DFS), locoregional recurrence-
free survival (LRFS), and distant metastasis-free survival
(DMFS) times were deﬁned as the time interval between
tumor excision and detection of ﬁrst disease recurrence,
locoregional recurrence or distant metastasis respectively or
the date of last follow-up. In 21 patients who developed
a second malignancy (excluding basal cell carcinoma), the
diagnosis date of the second malignancy was considered
Table 1: Clinicopathological and treatment features of the patients.
Feature Number of
patients %
Age, years
Median 48
Range 21–79
<35 72 7.8
≥35 852 92.2
Menopausal status
Premenopausal 494 53.5
Postmenopausal 430 46.5
Tumor size
T1 281 30.5
T2 541 58.5
T3 102 11.0
Histological type
Invasive ductal 789 85.3
Invasive lobular 67 7.3
Invasive ductal and lobular 31 3.4
Other 37 4.0
Surgery
Modiﬁed radical
mastectomy 828 89.6
Radical mastectomy 4 0.4
Breast-conserving 92 10.0
Adjuvant chemotherapy
Yes 814 88.1
No 110 11.9
Adjuvant hormonal therapy
Yes 642 69.5
No 282 30.5
Adjuvant radiotherapy
Yes 788 85.3
No 136 14.7
as the last followup date. In 9 patients whose death was
unrelated to cancer, the date of death was considered as the
lastfollow-update.Fifty-ﬁvepatientsdevelopedlocoregional
recurrence (including 16 patients who developed axillary
recurrence), 243 patients developed distant metastasis, and
9 patients developed concomitant locoregional recurrence
anddistantmetastasis;inpatientswithoutdiseaserecurrence
median follow-up time was 108.5 months.
2.2. Statistical Analysis. The Fisher exact test was used to
compare the axillary recurrence rates of the patient groups.
Patients were grouped according to the number of removed
and metastatic lymph nodes and LNR threshold value.
Kaplan-Meier method was used for calculation and plotting
of the DFS, LRFS, and DMFS curves of the patient groups,
and the log-rank test was used for the comparison of the
survival curves. The relative importance of the features
was investigated using the Cox proportional hazards model.ISRN Oncology 3
Table 2: Cox proportional hazards model analysis of the clinicopathological features and the number of removed lymph nodes in terms of
disease-free survival.
Feature Relative risk %95 CI P
Age, years 0.028
<35 1.00
≥35 0.65 0.45–0.95
Menopausal status 0.277
Premenopausal 1.00
Postmenopausal 0.86 0.66–1.12
Tumor size <0.001
T1 1.00
T2 2.16 1.60–2.91
T3 2.89 1.95–4.27
Histological type 0.080
Invasive ductal 1.00
Invasive lobular 1.07 0.70–1.63
Invasive ductal and lobular 1.21 0.68–2.12
Other 0.32 0.13–0.79
Adjuvant chemotherapy 0.998
Yes 1.00
No 1.00 0.66–1.50
Adjuvant hormonal therapy 0.003
Yes 1.00
No 1.43 1.12–1.83
Adjuvant radiotherapy 0.001
Yes 1.00
No 1.61 1.20–2.17
Number of removed LN 0.022
1–5 1.00
≥6 0.67 0.47–0.94
All comparisons were two tailed. P values less than 0.05
were considered to be statistically signiﬁcant. All statistical
analyses were performed using SPSS version 15.0 (SPSS, Inc.,
Chicago, Il, USA).
Survival analyses (for DFS, LRFS, and DMFS) were
performed separately for the whole series and for the patient
group having at least 10 lymph nodes removed from the
axilla. Patients were grouped in two diﬀerent ways according
tothenumberoflymphnodesremoved(groupingA:1–5,6–
9, 10–15 and 16 and more removed lymph nodes; grouping
B: 1–5 and 6 and more removed lymph nodes). To determine
the LNR threshold value that will separate patients in two
prognostic groups of low and high disease recurrence risk
with signiﬁcantly diﬀerent survival rates, survival analyses
wereconductedwithLNRthresholdvaluesbetween0.10 and
0.40 for the whole series, and between 0.10 and 0.25 for the
group with at least 10 lymph nodes removed, at increments
of 0.05. The LNR that produced the signiﬁcant survival
diﬀerence between the groups and gave the highest log-rank
x2 value was considered as the most signiﬁcant threshold
value.
3. Results
3.1. Survival according to the Number of Removed Lymph
Nodes in the Whole Series. The median number of removed
l y m p hn o d e sw a s1 2( r a n g e1 – 3 8 ) .
In grouping A, DFS was signiﬁcantly worse in patients
with 1–5 lymph node(s) removed compared to patients with
6–9 (P = 0.016), 10–15 (P = 0.024), and 16 and more (P
= 0.015) lymph nodes removed; there was no signiﬁcant
diﬀerence between the DFS of the three groups which had
6 or more lymph nodes removed (Figure 1). In grouping
B constructed based on this data, DFS of patients with
1–5 lymph node(s) removed was signiﬁcantly worse than
those with 6 or more lymph nodes removed (P = 0.008).
In multivariate Cox analysis, grouping B had independent
prognostic value (Table 2), whereas grouping A had not.
In grouping A, LRFS was signiﬁcantly worse in patients
with 1–5 lymph node(s) removed compared to patients with
6–9 (P = 0.008), 10–15 (P = 0.002) and 16 and more (P
= 0.009) lymph nodes removed; there was no signiﬁcant
diﬀerence between the LRFS of the three groups which had4 ISRN Oncology
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Figure 1: Disease-free survival rates according to the number of
lymph nodes removed from the axilla. Removed lymph node(s)
(RLN): 1–5 (85 patients) versus 6–9 (206 patients) (P = 0.016); 1–
5 versus 10–15 (394 patients) (P = 0.024); 1–5 versus ≥ 16 (239
patients) (P = 0.015); 6–9 versus 10–15 (P = 0.703); 6–9 versus ≥ 16
(P = 0.985); 10–15 versus ≥ 16 (P = 0.593).
6 or more lymph nodes removed. According to grouping
B, LRFS of patients with 1—5 lymph node(s) removed was
signiﬁcantly worse than patients with 6 or more lymph
nodesremoved(P =0.001).Bothgroupingshadindependent
prognostic value in Cox analysis (P = 0.005 and P < 0.001,
resp.).
In terms of DMFS there was no signiﬁcant diﬀerence
between patient groups according to either grouping A or B.
3.2. Axillary Recurrence in the Whole Series. Axillary recur-
rence was 9.4% (8/85 patients) in patients who had 1–5
lymph node(s) removed, while 0.9% (8/839 patients) in
patients who had 6 or more lymph nodes removed, and the
diﬀerence was signiﬁcant (P < 0.001).
3.3. Survival according to LNR in the Whole Series. The
median value of LNR was 0.143 (range 0.026–1.00) for the
whole series.
The most signiﬁcant LNR threshold value separating
patients in low- and high-risk groups in terms of DFS was
0.20 (P < 0.001) (Figure 2); this ratio had independent
prognostic signiﬁcance in Cox analysis (P < 0.001). When
grouping B, which is based on the number of lymph nodes
removed and has independent prognostic signiﬁcance, was
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Figure 2: Disease-free survival rates according to lymph node ratio
(LNR) in the whole series. LNR ≤ 0.20 (668 patients) versus LNR >
0.20 (256 patients) (log-rank x2 = 19.764, P < 0.001).
added to this analysis, its prognostic signiﬁcance was lost (P
= 0.527), while the signiﬁcance of LNR persisted (P < 0.001).
The most signiﬁcant LNR threshold value separating
patients in two risk groups in terms of LRFS was 0.30 (P
< 0.001) (Figure 3); this ratio had independent prognostic
signiﬁcance in Cox analysis (P < 0.001) (Table 3). When
groupings A and B were added to this analysis, their
prognostic signiﬁcance was lost (P = 0.325 and P = 0.190,
resp.), while the signiﬁcance of LNR persisted (P = 0.004 and
P = 0.006, resp.).
The most signiﬁcant threshold value separating patients
in two prognostic groups in terms of DMFS was 0.15 (P
< 0.001) (Figure 4); this ratio had independent prognostic
signiﬁcance in Cox analysis (P < 0.001) (Table 4).
3.4. Survival by the Number of Removed Lymph Nodes in
Patients with at Least 10 Lymph Nodes Removed. As men-
tioned above, there was no signiﬁcant relationship between
the number of removed lymph nodes and survival based on
any patient grouping for all three types of survival endpoint.
3.5. Survival by the Number of Metastatic Lymph Nodes in
Patients with at Least 10 Lymph Nodes Removed. DFS was
signiﬁcantlybetterinpatientswith1positivenodecompared
to those with 3 positive nodes; there was no signiﬁcant
diﬀerence between those with 1 and 2 positive node(s) orISRN Oncology 5
Table 3: Cox proportional hazards model analysis of the clinicopathological features and lymph node ratio in terms of locoregional
recurrence-free survival in the whole series.
Feature Relative risk %95 CI P
Age, years 0.737
<35 1.00
≥35 0.84 0.32–2.23
Menopausal status 0.863
Premenopausal 1.00
Postmenopausal 1.05 0.60–1.82
Tumor size 0.059
T1 1.00
T2 2.17 1.14–4.14
T3 2.08 0.82–5.25
Histological type 0.831
Invasive ductal 1.00
Invasive lobular 0.95 0.37–2.42
Invasive ductal and lobular 0.50 0.07–3.70
Other 0.61 0.15–2.53
Adjuvant chemotherapy 0.746
Yes 1.00
No 0.86 0.36–2.05
Adjuvant hormonal therapy 0.181
Yes 1.00
No 1.44 0.84–2.47
Adjuvant radiotherapy <0.001
Yes 1.00
No 3.78 2.17–6.59
Lymph node ratio <0.001
≤0.30 1.00
>0.30 3.14 1.94–5.99
2 and 3 positive nodes. Based on this, when patients were
grouped as those with 1 positive node versus 2-3 positive
nodes, DFS was signiﬁcantly better for patients with 1
positive node (P = 0.016); this grouping had independent
prognostic signiﬁcance in Cox analysis (P = 0.007).
There was no signiﬁcant relationship between the num-
ber of metastatic lymph nodes and LRFS.
DMFS of patients with 1 positive node was signiﬁcantly
better than those with 3 positive nodes; there was no
signiﬁcant diﬀerence between those with 1 and 2 positive
node(s) or 2 and 3 positive nodes. Based on this, when
patients were grouped as those with 1 positive node versus 2-
3 positive nodes, DMFS was signiﬁcantly better for patients
with 1 positive node (P = 0.022) (Figure 5); this grouping
had independent prognostic signiﬁcance in Cox analysis (P
= 0.017).
3.6. Survival by LNR in Patients with at Least 10 Lymph
Nodes Removed. The most signiﬁcant LNR threshold value
to separate patients in low- and high-risk groups in terms
of DFS was 0.15 (P = 0.005); this ratio had independent
prognostic signiﬁcance in Cox analysis (P = 0.001). When
the grouping based on metastatic lymph node number (1
positive versus 2-3 positives) was added to this analysis,
its prognostic signiﬁcance was lost (P = 0.294), while the
prognostic value of LNR moved slightly outside of the limit
of signiﬁcance (P = 0.064).
There was no signiﬁcant LNR threshold value to separate
patients in two prognostic groups in terms of LRFS.
The most signiﬁcant LNR threshold value to separate
patientsintwoprognosticgroupsintermsofDMFSwas0.15
(P < 0.001) (Figure 6); this ratio had independent prognostic
signiﬁcance in Cox analysis (P < 0.001). When the grouping
based on metastatic lymph node number (1 positive versus
2-3 positives) was added to this analysis, its prognostic
signiﬁcance was lost (P = 0.803), while LNR continued to be
a signiﬁcant prognostic factor (P = 0.010).
4. Discussion
In our series composed of patients with breast carcinoma
having 1–3 metastatic axillarylymph node(s), DFSand LRFS
of patients with 1–5 lymph node(s) removed from their
axilla were signiﬁcantly worse than those with 6 or more6 ISRN Oncology
Table 4:Coxproportionalhazardsmodelanalysisoftheclinicopathologicalfeaturesandlymphnoderatiointermsofdistantmetastasis-free
survival in the whole series.
Feature Relative risk %95 CI P
Age, years 0.009
<35 1.00
≥35 0.58 0.39–0.87
Menopausal status 0.148
Premenopausal 1.00
Postmenopausal 0.80 0.60–1.08
Tumor size <0.001
T1 1.00
T2 2.13 1.53–2.97
T3 2.94 1.92–4.51
Histological type 0.042
Invasive ductal 1.00
Invasive lobular 1.08 0.68–1.71
Invasive ductal and lobular 1.50 0.85–2.64
Other 0.24 0.07–0.75
Adjuvant chemotherapy 0.986
Yes 1.00
No 1.00 0.63–1.58
Adjuvant hormonal therapy 0.016
Yes 1.00
No 1.39 1.06–1.82
Adjuvant radiotherapy 0.037
Yes 1.00
No 1.47 1.02–2.12
Lymph node ratio <0.001
≤0.15 1.00
>0.15 1.72 1.33–2.23
lymph nodes removed, and this grouping had independent
prognostic signiﬁcance for both types of survival outcomes.
In patient groups with more than 5 lymph nodes removed,
there was no signiﬁcant relationship between the increased
number of removed lymph nodes and DFS or LRFS. There
was no signiﬁcant relationship between the number of
removed lymph nodes and DMFS.
Studies involving patients with 1–3 axillary lymph node
metastasis indicate signiﬁcantly better overall survival [32]
and disease-free survival [33] with increasing number of
lymph nodes removed. Karlsson et al. determined that in
node-positive patients who did not receive radiotherapy,
locoregional recurrence decreased signiﬁcantly with increas-
ing number of nonmetastatic lymph nodes removed and
indicated that patients with 1–3 positive nodes and less than
10 nonmetastatic lymph nodes removed are candidates for
postmastectomy radiotherapy, since their 10 year cumulative
locoregional recurrence incidence is over 20% [34]. In
a study by Schaapveld et al., overall survival was found
to be signiﬁcantly worse in patients with less than 10
lymph nodes removed compared to patients with 10 or
more nodes removed; however, since overall survival can
be deceptive as it includes all deaths along with nonbreast
cancer related deaths, relative survival (the ratio of the
overall survival and the expected survival) was analyzed
and the number of removed lymph nodes was shown to be
nonsigniﬁcant [8]. Truong et al. did not observe a signiﬁcant
relationship between the number of lymph nodes removed
and locoregional recurrence, distant metastasis, and overall
survival rates [29].
In our series, axillary recurrence rate was signiﬁcantly
higher in patients with 1–5 lymph node(s) removed (9.4%)
compared to those with 6 or more nodes removed (0.9%).
It is generally accepted that a suﬃcient axillary dissection
to avoid leaving probable metastatic lymph nodes behind
is necessary for surgical control of the disease in the axilla
and for correct evaluation of the axillary status in node-
positive patients. Our study results conﬁrm this approach:
high rate of axillary recurrence in patients with few lymph
nodes removed indicates that actually there may be more
than three metastatic lymph nodes in the axilla (N2 maybe
N3 disease) and that these may have been left in the axilla.ISRN Oncology 7
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Figure 3: Locoregional recurrence-free survival rates according to
l y m p hn o d er a t i o( L N R )i nt h ew h o l es e r i e s .L N R≤ 0.30 (797
patients) versus LNR > 0.30 (127 patients) (log-rank x2 = 17.611,
P < 0.001).
In our study, the most signiﬁcant LNR threshold value
separating patients in low- and high-risk groups with sig-
niﬁcant survival diﬀerence was 0.20 for DFS, 0.30 for LRFS,
and 0.15 for DMFS. All three LNR threshold values had
independent prognostic signiﬁcance in Cox analysis. When
grouping B (with patients grouped according to 1–5 lymph
node(s) removed versus 6 or more nodes removed) which
had independent prognostic signiﬁcance was added to these
Cox analyses conducted for DFS and LRFS, its signiﬁcance
was lost, while the prognostic signiﬁcance of LNR threshold
values persisted. Since LNR is a derivative of the number
of metastatic lymph nodes and the number of lymph nodes
removed, it should not be included in the Cox analysis with
one of these two parameters. The prognostic signiﬁcance of
LNR is superior to the number of lymph nodes removed
for DFS and LRFS, and LNR has independent prognostic
signiﬁcance for DMFS while the number of removed lymph
nodes has not; thus, LNR can be used to separate patients
with N1 disease in low- and high-risk groups regardless of
the total number of lymph nodes removed.
Series of patients having 1–3 positive lymph node(s)
showed that patients with high LNR have worse survival
comparedtothosewithlowLNR:Truongetal.,intheirseries
of patients having 1–39 node(s) removed and not receiving
radiotherapy, determined the most signiﬁcant LNR thresh-
old value for locoregional recurrence, distant metastasis,
and overall survival as 0.25, and recommended radiotherapy
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Figure 4: Distant metastasis-free survival rates according to lymph
node ratio (LNR) in the whole series. LNR ≤ 0.15 (501 patients)
versus LNR > 0.15 (423 patients) (log-rank x2 = 17.667, P < 0.001).
following mastectomy for patients with LNR > 0.25 [29].
Also, in another series of patients having 1–41 lymph
node(s) removed and not receiving radiotherapy, Truong
et al. indicated that in terms of locoregional recurrence
prediction, LNR was more valuable than the number of
metastatic lymph nodes and recommended postmastectomy
radiotherapy for patients with LNR > 0.20, since their
10-year locoregional recurrence risk was above 20% [31].
Yildirim and Berberoglu, in their series of patients having at
least 10 lymph nodes removed and not receiving radiother-
apy,determinedthemostsigniﬁcantLNRthresholdvaluefor
prediction of locoregional recurrence risk as 0.15 [30].
In our study, diﬀerent threshold values for most signiﬁ-
cant LNR for DFS, LRFS, and DMFS were identiﬁed. If the
survival analyses of this study were performed for DFS only,
the threshold value of 0.20 would have been higher than the
most signiﬁcant threshold value for DMFS (0.15) and 167
patients with LNR > 0.15–0.20 would have been classiﬁed as
with low risk despite their high risk for distant metastasis.
Although in daily practice, it may be diﬃcult to determine a
diﬀerent threshold value for each type of disease recurrence,
its potential use in planning a more appropriate adjuvant
therapy should be taken into consideration.
Yildirim and Berberoglu in their series of all node-
positive patients with at least 10 lymph nodes removed
from the axilla, identiﬁed the optimum LNR threshold value
as 0.15 for locoregional recurrence and 0.20 for distant8 ISRN Oncology
0 1 22 43 64 86 07 2
Time (months)
1
0.9
0.8
0.7
0.6
0.5
1 positive LN
2-3 positive LN
D
i
s
t
a
n
t
m
e
t
a
s
t
a
s
i
s
-
f
r
e
e
s
u
r
v
i
v
a
l
r
a
t
e
Figure 5: Distant metastasis-free survival rates according to the
number of metastatic lymph nodes (LN) in patients with at least
10 LN removed. 1 positive (285 patients) versus 2-3 positives (348
patients) (P = 0.022).
metastasis and determined signiﬁcantly higher disease recur-
rence rates in patients having a LNR above these thresholds
[15].
In our study, survival analyses were conducted separately
for patients with at least 10 lymph nodes removed. It is
generally accepted that at least 10 lymph nodes need to
be removed in order to classify nodal disease based on
the number of metastatic lymph nodes according to TNM
classiﬁcation [8, 12, 35, 36]. Nodal disease classiﬁcation
cannot be done in patients having less than 10 lymph nodes
removed, while that was the case with some of the patients
in our series. When at least 10 lymph nodes are removed
from the axilla and metastasis is found in 1–3 of them,
these patients are classiﬁed as with N1 disease by TNM
classiﬁcation, and thus are accepted as a homogenous group.
However, our study results suggest that N1 disease does not
constitute a homogenous prognostic group: when patients
were grouped according to the number of metastatic lymph
nodes, DFS and DMFS were signiﬁcantly better in patients
with 1 positive node compared to 2-3 positive nodes and this
grouping had prognostic signiﬁcance independent of age,
menopausal status, tumor size, histological type, adjuvant
chemotherapy,radiotherapy,andhormonaltherapy.Patients
with LNR > 0.15 had signiﬁcantly worse DFS and DMFS,
and LNR had independent prognostic signiﬁcance according
to this threshold value in Cox analysis; when a grouping
based on the number of metastatic lymph nodes was added
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Figure 6: Distant metastasis-free survival rates according to lymph
node ratio (LNR) in patients with at least 10 lymph nodes removed.
LNR ≤ 0.15 (433 patients) versus LNR > 0.15 (200 patients) (log-
rank x2 = 12.130, P < 0.001).
to these analyses, its prognostic signiﬁcance was lost, while
theprognosticsigniﬁcanceofLNRpersistedthoughitmoved
a little outside of the limit of signiﬁcance for DFS (P =
0.064). Moreover, as also mentioned above, LNR should be
included in the Cox regression analysis alone, as it is derived
from the number of removed and metastatic lymph nodes.
According to these results, LNR, which is a more powerful
prognostic factor than the number of metastatic lymph
nodes, can be used to separate N1 disease patients having
at least 10 lymph nodes removed into low- and high-risk
prognostic groups for distant metastasis development, thus
providing more detailed and useful prognostic information
than TNM nodal disease classiﬁcation. In patients having
10 or more lymph nodes removed, number of removed and
metastatic lymph nodes and LNR did not have prognostic
signiﬁcance for LRFS. This result indirectly suggests that
in N1 disease, removal of at least 10 lymph nodes may be
suﬃcienttoobtainlocoregionalcontrolandremovalofmore
lymph nodes may not be related to locoregional recurrence,
and hence, N1 disease may be homogeneous in terms of
locoregional control.
5. Conclusions
Irrespectiveofthenumberoflymphnodesremovedfromthe
axilla, LNR is a useful tool in separating breast carcinoma
patients with 1–3 metastatic lymph node(s) into low- andISRN Oncology 9
high-risk prognostic groups. Thus, LNR may be useful to
standardize adjuvant therapy for patients operated in hos-
pitals that use diﬀerent axillary dissection width and have
diﬀerent median number of removed lymph nodes as well
as to draw reliably comparisons between treatment results
coming from such diﬀerent hospitals.
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